Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • optical333 optical333 Feb 1, 2013 10:37 AM Flag

    reason to hang tough w patience

    October, A 13G filing has disclosed that Ridgeback Capital, a healthcare focused hedge fund managed by Wayne Holman, has acquired a total of 3.8 million shares of Celldex Therapeutics CLDX +0.13% . This gives it over 6% of the $410 million market cap pharmaceutical company's total shares outstanding. Ridgeback had reported owning 2.9 million shares of the stock at the beginning of October

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • NEW YORK, NY--(Marketwire - Jan 24, 2013) - Lost revenues from expiring patents has played a major part in the Biotech Industry's success in recent years. A total of 676 takeovers of biotechnology and pharmaceutical companies have occurred in the past three years, with an average premium of 38 percent, according to data collected by Bloomberg. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Antares Pharma Inc. ( NASDAQ : ATRS ) and Celldex Therapeutics, Inc. ( NASDAQ : CLDX ).

      Sentiment: Buy

 
CLDX
3.8164-0.0136(-0.36%)2:33 PMEDT